Gyre Therapeutics (GYRE) Liabilities and Shareholders Equity (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $162.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 24.83% year-over-year to $162.0 million; the TTM figure through Mar 2026 stood at $640.2 million (up 27.69% YoY), while the FY2025 annual figure was $166.1 million, up 32.48% from the prior year.
• Liabilities and Shareholders Equity eased to $162.0 million in Q1 2026 per GYRE's latest filing, from $166.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $166.1 million in Q4 2025 and bottomed at $10.0 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $97.7 million across 5 years, with a median of $120.9 million in 2024.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity tumbled 85.13% — and 2024, when it surged 1156.92%.
• Gyre Therapeutics' Liabilities and Shareholders Equity stood at $84.8 million in 2022, then surged by 37.5% to $116.5 million in 2023, then climbed by 7.61% to $125.4 million in 2024, then jumped by 32.48% to $166.1 million in 2025, then fell by 2.48% to $162.0 million in 2026.
• Business Quant data shows GYRE's Liabilities and Shareholders Equity at $162.0 million in Q1 2026, $166.1 million in Q4 2025, and $159.4 million in Q3 2025.